ACR 50 Response

ACR 50 Response

A measure—based on American College of Rheumatology criteria—of at least a 50% improvement in the number of tender and swollen joints, and a 50% improvement in at least 3 of the following: the patient’s global assessment of disease status; the patient’s assessment of pain; the patient’s assessment of function—measured using the Stanford Health Assessment Questionnaire—the physician’s global assessment of disease status; serum C-reactive protein levels.
References in periodicals archive ?
The researchers wanted to find out which of these approaches would sufficiently alleviate symptoms to reach an ACR 50 response, which indicates a 50 percent improvement in the number of tender or swollen joints and other criteria including pain, disability, and the doctor's assessment of disease severity.
In addition, statistically significantly superior responses were also seen in ACR 50 response rates for the 5, 10 and 15 mg twice daily doses and in the ACR 70 response rates for the 10 and 15 mg twice-daily doses.
More than half of patients are achieving an ACR 50 response, and increasingly that is what we are aiming at.
After 2 years of treatment, 42% of patients in the high-dose doxycycline group met the ACR 50 response outcome, as did 33% of the low-dose doxycycline group.
Emery showed that subjects treated with high dose CRx-139 (3mg of prednisolone and 20mg of paroxetine) showed a benefit in ACR 50 response compared to low dose CRx-139 (3mg of prednisolone and 10mg of paroxetine) or 3mg of prednisolone alone.
Two patients had an ACR 50 response, and one achieved an ACR 70, said Dr.
Nearly half of the infliximab patients had an ACR 50 response or better vs.
Of patients treated with an open-label second course of AMEVIVE and methotrexate, 32 percent achieved an ACR 50 response and 12 percent achieved ACR 70 at week 48.
ACR 50 response rates are around 50% and 37%; ACR 70 response rates are 13% and 9%, respectively.
17% of patients treated with AMEVIVE and methotrexate achieved an ACR 50 response and 7% achieved ACR 70, in contrast to 10% and 2% of patients respectively in the methotrexate alone group
In this group at 24 weeks, 73% achieved an American College of Rheumatology (ACR) 20 response, 43% achieved an ACR 50 response, and 23% reached an ACR 70 response.
Nearly half of the infliximab patients--46% receiving 3 mg/kg and 50% receiving 6 mg/kg--achieved an ACR 50 response or better versus 32% of the methotrexate-only group.